Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA.

Kiakos K, Englinger B, Yanow SK, Wernitznig D, Jakupec MA, Berger W, Keppler BK, Hartley JA, Lee M, Patil PC.

Bioorg Med Chem Lett. 2018 May 1;28(8):1342-1347. doi: 10.1016/j.bmcl.2018.03.016. Epub 2018 Mar 5.

PMID:
29548574
2.

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.

Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D.

Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20.

3.

ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, Marafioti T, Britten CE, Havenith CEG, Chivers S, D'Hooge F, Williams DG, Tiberghien A, Howard PW, Hartley JA, van Berkel PH.

Blood. 2018 Mar 8;131(10):1094-1105. doi: 10.1182/blood-2017-10-813493. Epub 2018 Jan 3.

PMID:
29298756
4.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
5.

The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer.

Flynn MJ, Hartley JA.

Br J Haematol. 2017 Oct;179(1):20-35. doi: 10.1111/bjh.14770. Epub 2017 May 30. Review.

PMID:
28556984
6.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

7.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

8.

Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin.

Kemp GC, Tiberghien AC, Patel NV, D'Hooge F, Nilapwar SM, Adams LR, Corbett S, Williams DG, Hartley JA, Howard PW.

Bioorg Med Chem Lett. 2017 Mar 1;27(5):1154-1158. doi: 10.1016/j.bmcl.2017.01.074. Epub 2017 Jan 30.

PMID:
28188066
9.

Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.

Tiberghien AC, Levy JN, Masterson LA, Patel NV, Adams LR, Corbett S, Williams DG, Hartley JA, Howard PW.

ACS Med Chem Lett. 2016 May 24;7(11):983-987. eCollection 2016 Nov 10.

10.

Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours.

Childs A, Vesely C, Ensell L, Lowe H, Luong TV, Caplin ME, Toumpanakis C, Thirlwell C, Hartley JA, Meyer T.

Br J Cancer. 2016 Dec 6;115(12):1540-1547. doi: 10.1038/bjc.2016.377. Epub 2016 Nov 22.

11.

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CE, Levy JN, Tiberghien A, Masterson LA, Barry C, D'Hooge F, Marafioti T, Parren PW, Williams DG, Howard PW, van Berkel PH, Hartley JA.

Mol Cancer Ther. 2016 Nov;15(11):2709-2721. Epub 2016 Aug 17.

12.

Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.

Pett L, Kiakos K, Satam V, Patil P, Laughlin-Toth S, Gregory M, Bowerman M, Olson K, Savagian M, Lee M, Lee M, Wilson WD, Hochhauser D, Hartley JA.

Biochim Biophys Acta. 2017 May;1860(5):617-629. doi: 10.1016/j.bbagrm.2016.10.005. Epub 2016 Oct 24.

PMID:
27750031
13.

A comparison of CellCollector with CellSearch in patients with neuroendocrine tumours.

Mandair D, Vesely C, Ensell L, Lowe H, Spanswick V, Hartley JA, Caplin ME, Meyer T.

Endocr Relat Cancer. 2016 Oct;23(10):L29-32. doi: 10.1530/ERC-16-0201. Epub 2016 Aug 12. No abstract available.

14.

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.

Vena F, Hartley JA, Hochhauser D.

Clin Cancer Res. 2016 May 15;22(10):2595. doi: 10.1158/1078-0432.CCR-16-0566. No abstract available. Erratum in: Clin Cancer Res. 2016 Nov 15;22(22):5619.

15.

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.

Santoro V, Jia R, Thompson H, Nijhuis A, Jeffery R, Kiakos K, Silver AR, Hartley JA, Hochhauser D.

J Natl Cancer Inst. 2015 Dec 30;108(6):djv394. doi: 10.1093/jnci/djv394. Print 2016 Jun.

16.

NF-Y activates genes of metabolic pathways altered in cancer cells.

Benatti P, Chiaramonte ML, Lorenzo M, Hartley JA, Hochhauser D, Gnesutta N, Mantovani R, Imbriano C, Dolfini D.

Oncotarget. 2016 Jan 12;7(2):1633-50. doi: 10.18632/oncotarget.6453.

17.

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.

Colmegna B, Uboldi S, Frapolli R, Licandro SA, Panini N, Galmarini CM, Badri N, Spanswick VJ, Bingham JP, Kiakos K, Erba E, Hartley JA, D'Incalci M.

Br J Cancer. 2015 Dec 22;113(12):1687-93. doi: 10.1038/bjc.2015.407. Epub 2015 Dec 3.

18.

Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.

VanBrunt MP, Shanebeck K, Caldwell Z, Johnson J, Thompson P, Martin T, Dong H, Li G, Xu H, D'Hooge F, Masterson L, Bariola P, Tiberghien A, Ezeadi E, Williams DG, Hartley JA, Howard PW, Grabstein KH, Bowen MA, Marelli M.

Bioconjug Chem. 2015 Nov 18;26(11):2249-60. doi: 10.1021/acs.bioconjchem.5b00359. Epub 2015 Sep 11.

PMID:
26332743
19.

Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.

Mellinas-Gomez M, Spanswick VJ, Paredes-Moscosso SR, Robson M, Pedley RB, Thurston DE, Baines SJ, Stell A, Hartley JA.

BMC Vet Res. 2015 Aug 19;11:215. doi: 10.1186/s12917-015-0534-2.

20.

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).

Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D.

Clin Cancer Res. 2015 Dec 15;21(24):5563-77. doi: 10.1158/1078-0432.CCR-15-0485. Epub 2015 Jul 30.

21.

Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms.

Khan MS, Kirkwood AA, Tsigani T, Lowe H, Goldstein R, Hartley JA, Caplin ME, Meyer T.

Clin Cancer Res. 2016 Jan 1;22(1):79-85. doi: 10.1158/1078-0432.CCR-15-1008. Epub 2015 Jul 21.

22.

AzaHx, a novel fluorescent, DNA minor groove and G·C recognition element: Synthesis and DNA binding properties of a p-anisyl-4-aza-benzimidazole-pyrrole-imidazole (azaHx-PI) polyamide.

Satam V, Babu B, Patil P, Brien KA, Olson K, Savagian M, Lee M, Mepham A, Jobe LB, Bingham JP, Pett L, Wang S, Ferrara M, Bruce CD, Wilson WD, Lee M, Hartley JA, Kiakos K.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3681-5. doi: 10.1016/j.bmcl.2015.06.055. Epub 2015 Jun 19.

PMID:
26122210
23.

Nuclear Localization and Gene Expression Modulation by a Fluorescent Sequence-Selective p-Anisyl-benzimidazolecarboxamido Imidazole-Pyrrole Polyamide.

Kiakos K, Pett L, Satam V, Patil P, Hochhauser D, Lee M, Hartley JA.

Chem Biol. 2015 Jul 23;22(7):862-75. doi: 10.1016/j.chembiol.2015.06.005. Epub 2015 Jun 25.

24.

A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer.

Ohnmacht SA, Marchetti C, Gunaratnam M, Besser RJ, Haider SM, Di Vita G, Lowe HL, Mellinas-Gomez M, Diocou S, Robson M, Šponer J, Islam B, Pedley RB, Hartley JA, Neidle S.

Sci Rep. 2015 Jun 16;5:11385. doi: 10.1038/srep11385.

25.

WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway.

Tomas A, Vaughan SO, Burgoyne T, Sorkin A, Hartley JA, Hochhauser D, Futter CE.

Nat Commun. 2015 Jun 12;6:7324. doi: 10.1038/ncomms8324.

26.

Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.

Ip LR, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, Hochhauser D, Hartley JA, Sasaki T, Gewinner CA.

Oncotarget. 2015 Apr 30;6(12):10548-62.

27.

Therapeutic Agents Based on DNA Sequence Specific Binding.

Pett L, Hartley JA, Kiakos K.

Curr Top Med Chem. 2015;15(14):1293-322. Review.

PMID:
25866278
28.

Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining.

Cook R, Zoumpoulidou G, Luczynski MT, Rieger S, Moquet J, Spanswick VJ, Hartley JA, Rothkamm K, Huang PH, Mittnacht S.

Cell Rep. 2015 Mar 31;10(12):2006-18. doi: 10.1016/j.celrep.2015.02.059. Epub 2015 Mar 26.

29.

Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage.

Liccardi G, Hartley JA, Hochhauser D.

Clin Cancer Res. 2014 Jul 1;20(13):3496-506. doi: 10.1158/1078-0432.CCR-13-2695. Epub 2014 Apr 29.

30.

Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.

Bhosle J, Kiakos K, Porter AC, Wu J, Makris A, Hartley JA, Hochhauser D.

Mol Cancer Ther. 2013 Dec;12(12):2897-908. doi: 10.1158/1535-7163.MCT-12-1049. Epub 2013 Oct 3.

31.

An extended pyrrolobenzodiazepine-polyamide conjugate with selectivity for a DNA sequence containing the ICB2 transcription factor binding site.

Brucoli F, Hawkins RM, James CH, Jackson PJ, Wells G, Jenkins TC, Ellis T, Kotecha M, Hochhauser D, Hartley JA, Howard PW, Thurston DE.

J Med Chem. 2013 Aug 22;56(16):6339-51. doi: 10.1021/jm4001852. Epub 2013 Jul 26.

PMID:
23889553
32.

Affinity and kinetic modulation of polyamide-DNA interactions by N-modification of the heterocycles.

Ramos JP, Babu B, Chavda S, Liu Y, Plaunt A, Ferguson A, Savagian M, Lee M, Tzou S, Lin S, Kiakos K, Wang S, Lee M, Hartley JA, Wilson WD.

Biopolymers. 2013 Aug;99(8):497-507. doi: 10.1002/bip.22205.

33.

Design, synthesis, and DNA binding characteristics of a group of orthogonally positioned diamino, N-formamido, pyrrole- and imidazole-containing polyamides.

Chavda S, Babu B, Patil P, Plaunt A, Ferguson A, Lee M, Tzou S, Sjoholm R, Rice T, Mackay H, Ramos J, Wang S, Lin S, Kiakos K, Wilson WD, Hartley JA, Lee M.

Bioorg Med Chem. 2013 Jul 1;21(13):3907-18. doi: 10.1016/j.bmc.2013.04.001. Epub 2013 Apr 10.

PMID:
23647824
34.

GC-targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models.

Rahman KM, Jackson PJ, James CH, Basu BP, Hartley JA, de la Fuente M, Schatzlein A, Robson M, Pedley RB, Pepper C, Fox KR, Howard PW, Thurston DE.

J Med Chem. 2013 Apr 11;56(7):2911-35. doi: 10.1021/jm301882a. Epub 2013 Mar 21.

PMID:
23514599
35.

Hx-amides: DNA sequence recognition by the fluorescent Hx (p-anisylbenzimidazole)•pyrrole and Hx•imidazole pairings.

Satam V, Patil P, Babu B, Gregory M, Bowerman M, Savagian M, Lee M, Tzou S, Olson K, Liu Y, Ramos J, Wilson WD, Bingham JP, Kiakos K, Hartley JA, Lee M.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1699-702. doi: 10.1016/j.bmcl.2013.01.075. Epub 2013 Jan 25.

PMID:
23395654
36.

γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).

Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA.

Clin Cancer Res. 2013 Feb 1;19(3):721-30. doi: 10.1158/1078-0432.CCR-12-2529. Epub 2012 Dec 18.

37.

Circulating tumor cells as prognostic markers in neuroendocrine tumors.

Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T.

J Clin Oncol. 2013 Jan 20;31(3):365-72. doi: 10.1200/JCO.2012.44.2905. Epub 2012 Dec 17.

PMID:
23248251
38.

Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.

Garelnabi EA, Pletsas D, Li L, Kiakos K, Karodia N, Hartley JA, Phillips RM, Wheelhouse RT.

ACS Med Chem Lett. 2012 Sep 18;3(12):965-8. doi: 10.1021/ml300132t. eCollection 2012 Dec 13.

39.

Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation.

Kirby J, Highley JR, Cox L, Goodall EF, Hewitt C, Hartley JA, Hollinger HC, Fox M, Ince PG, McDermott CJ, Shaw PJ.

Neuropathol Appl Neurobiol. 2013 Aug;39(5):562-71. doi: 10.1111/nan.12007.

40.

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.

Anthoney DA, Naik J, Macpherson IR, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves C, Evans TR.

BMC Cancer. 2012 Nov 21;12:536. doi: 10.1186/1471-2407-12-536.

41.

Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

Spanswick VJ, Lowe HL, Newton C, Bingham JP, Bagnobianchi A, Kiakos K, Craddock C, Ledermann JA, Hochhauser D, Hartley JA.

BMC Cancer. 2012 Sep 28;12:436. doi: 10.1186/1471-2407-12-436.

42.

Synthesis and DNA binding properties of 1-(3-aminopropyl)-imidazole-containing triamide f-Im*PyIm: a novel diamino polyamide designed to target 5'-ACGCGT-3'.

Satam V, Babu B, Porte A, Savagian M, Lee M, Smeltzer T, Liu Y, Ramos J, Wilson WD, Lin S, Kiakos K, Hartley JA, Lee M.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5898-902. doi: 10.1016/j.bmcl.2012.07.071. Epub 2012 Jul 27.

PMID:
22892118
43.

Characterization of the human SNM1A and SNM1B/Apollo DNA repair exonucleases.

Sengerová B, Allerston CK, Abu M, Lee SY, Hartley J, Kiakos K, Schofield CJ, Hartley JA, Gileadi O, McHugh PJ.

J Biol Chem. 2012 Jul 27;287(31):26254-67. doi: 10.1074/jbc.M112.367243. Epub 2012 Jun 11.

44.

Antibody-drug conjugates - a perfect synergy.

Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA.

Expert Opin Biol Ther. 2012 Sep;12(9):1191-206. doi: 10.1517/14712598.2012.693473. Epub 2012 Jun 1. Review.

PMID:
22650648
45.

Small molecule drugs - optimizing DNA damaging agent-based therapeutics.

Hartley JA, Hochhauser D.

Curr Opin Pharmacol. 2012 Aug;12(4):398-402. doi: 10.1016/j.coph.2012.03.008. Epub 2012 Apr 11. Review.

PMID:
22503290
46.

Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.

Pan X, Hartley JM, Hartley JA, White KN, Wang Z, Bligh SW.

Phytomedicine. 2012 May 15;19(7):618-24. doi: 10.1016/j.phymed.2012.02.003. Epub 2012 Mar 6.

PMID:
22402246
47.

Minor structural modifications to alchemix influence mechanism of action and pharmacological activity.

Abdallah QM, Phillips RM, Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse RT, Kiakos K, Bingham JP, Hartley JA, Patterson LH, Pors K.

Biochem Pharmacol. 2012 Jun 1;83(11):1514-22. doi: 10.1016/j.bcp.2012.02.017. Epub 2012 Mar 1.

PMID:
22387433
48.

Novel diamino imidazole and pyrrole-containing polyamides: Synthesis and DNA binding studies of mono- and diamino-phenyl-ImPy*Im polyamides designed to target 5'-ACGCGT-3'.

Satam V, Babu B, Chavda S, Savagian M, Sjoholm R, Tzou S, Ramos J, Liu Y, Kiakos K, Lin S, David Wilson W, Hartley JA, Lee M.

Bioorg Med Chem. 2012 Jan 15;20(2):693-701. doi: 10.1016/j.bmc.2011.12.010. Epub 2011 Dec 14. Erratum in: Bioorg Med Chem. 2012 Aug 1;20(15):4881. Ramos, Joseph [added].

PMID:
22222156
49.

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.

Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH.

Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14.

PMID:
22002321
50.

Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.

Wang AT, Sengerová B, Cattell E, Inagawa T, Hartley JM, Kiakos K, Burgess-Brown NA, Swift LP, Enzlin JH, Schofield CJ, Gileadi O, Hartley JA, McHugh PJ.

Genes Dev. 2011 Sep 1;25(17):1859-70. doi: 10.1101/gad.15699211.

Supplemental Content

Loading ...
Support Center